UBS has issued new research reports this week and has identified two companies with market-moving news they think are worth a look.

Let’s see who they like.

Nufarm Ltd (ASX: NUF)

Nufarm shares are up by more than a third over the past 12 months but UBS believes the stock still has a way to run.

The company this week put out new earnings guidance, saying it expected underlying EBITDA to increase by about 25% for the full year.

The company’s seed technologies division was expected to deliver strong growth, led by growth in hybrid seeds and improved omega-3 pricing.

The company’s crop protection division however was expected to have flat earnings.

On the negative side of the ledger Nufarm said it expected to book $90-$110 million in write downs.

UBS said the expected result was a 2%-3% downgrade to previous expectations.

The broker has a price target of $3.50 on Nufarm shares compared to $3.12 currently.

Telix Pharmaceuticals Ltd (ASX: TLX)

UBS has a very bullish price target on Telix after attending an R&D day which the broker said, “showcased the meaningful clinical development for TLX’s diagnostics and therapeutics pipeline across prostate, brain, and kidney cancers”.

The broker said key highlights included progress on prostate cancer therapeutics as well as the company’s Pixclara brain cancer imaging agent.

UBS said:

We believe the event further highlighted TLX’s growing breadth and depth across precision medicine and therapeutics towards being a leading radiopharma business. We see multiple opportunities for meaningful value creation on the horizon, supported by TLX’s deep expertise and clinical development experience with key catalysts over the next 12 months being resubmission/approval for Zircaix, topline data from BiPASS, topline data for TLX597, and data updates from ProstAct Global trial. Furthermore, we believe the recent deal with ITM improves isotope supply chain for ongoing therapeutic portfolio development, creates cost synergy, and adds additional therapeutic pipelines.

Telix just this week announced the $3.3 billion merger deal with ITM, which, Telix said, is the world’s leading supplier of therapeutic radioisotopes and the only producer of globally-scaled, commercial-grade lutetium-77.

Telix said regarding the deal:

The merger will further strengthen Telix’s leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organisation will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry’s most extensive therapeutic radiopharmaceutical pipeline.

Telix said ITM grew at a compound annual rate of 40% from 2021 to 2025 and generated US$273 million in revenue in 2025.

UBS has a price target of $22 on Telix shares compared to the current price of $16.01.

The post 2 ASX shares UBS says could increase 13% to 37% appeared first on The Motley Fool Australia.

More reading

• 5 ASX 200 shares upgraded by experts this week
• Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares
• What is Bell Potter’s updated view on Nufarm shares after crashing 6%
• 5 things to watch on the ASX 200 on Thursday
• Why is this ASX share crashing 8% on Wednesday?

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Bank of Queensland Ltd (ASX: BOQ), Harvey Norman Ltd (ASX: HVN) and Lynas Rare Earths Ltd (ASX: LYC) shares are in focus today amid a combination of analyst updates and shifting investor sentiment.

Let’s find out how these stocks are tracking, and what brokers expect next.

Brokers rate Lynas shares as a BUY

Lynas shares have fallen around 2% in Friday morning trade, to $14.10 a piece. The shares are now up around 15% for the year-to-date but are 17% below trading levels 12 months ago.

The downturn is down to a couple of factors which have combined to create headwinds for the ASX rare earths miner. Geopolitical volatility, higher costs, and investors taking their gains off the table after a strong rally earlier this year, have all dampened the share price.

But late last month the company posted a record FY26 profit and revenue as company growth continues to ramp up. Lynas reported a 76% increase in revenue and a 282% increase in EBITDA. 

The company also confirmed it is focused on ramping up new assets in FY27, and growing its global presence.

It looks like analysts are excited by Lynas’ potential. TradingView data shows the majority have a buy/strong buy rating on the shares. The average $19.57 target price implies a 39% upside, at the time of writing.

Brokers rate Harvey Norman shares as a HOLD

Harvey Norman shares are flat at $4.17 this morning. It’s been a difficult year for the retailer and its shares have shed 41% of their value so far in 2026. They’re also 43% lower than 12 months ago.

Harvey Norman has faced strong headwinds this year following renewed concerns about rising inflation and its impact on consumer spending. A tighter household budget means Australians have lowered their discretionary spending this year. 

The experts are on the fence about where the shares could go over the next 12 months. TradingView data shows six (out of 14) analysts have a hold rating on Harvey Norman. Another five rate the shares a sell/strong sell and three rate the shares as a buy/strong buy.

The $4.46 average target price implies a potential 7% upside ahead, at the time of writing.

Brokers rate BOQ shares as a SELL

BOQ shares have been relatively stable through September so far hovering between $6.50 and $6.70 a piece. It’s good news for investors after the ASX bank shares were caught up in a bank-sector-wide sell-off last month. 

At the time of writing the shares are also flat at $6.51 a piece. The shares are now down around 1% for the year-to-date and 9% lower than 12 months ago.

The bank is scheduled to post its FY26 results in three weeks time (on the 15th of October) and it looks like investors are sitting tight while they wait for an update on the bank’s revenue, net interest margin and final dividend call.

It looks like the shares are still considered to be trading above fair value. TradingView data shows the majority have a sell/strong sell rating on the shares. The $6.09 average target price implies a downside of around 6% at the time of writing. 

The post Buy, hold, sell: BOQ, Harvey Norman, Lynas shares appeared first on The Motley Fool Australia.

More reading

• How much superannuation do I need to earn $1,000 per week in passive income?
• Bank of Queensland shares hit a 52-week low in June. Are they cheap today?
• Downgrade alert! 5 ASX 200 shares downgraded by experts this week
• ASX retail shares are down 13% in 2026. Here’s what Morgan Stanley is worried about
• Starting with $20,000, how to build a portfolio generating $5,000 a year in passive income

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

After a rough couple of years, CSL Ltd (ASX: CSL) is getting some attention from Australia’s fund managers.

According to The Australian, new research from Morgan Stanley shows fundies been making some interesting changes to their portfolios.

And CSL is one of the stocks they’ve been buying.

CSL shares are currently down 0.40% to $178.41 in morning trade, following yesterday’s close of $179.12.

So, what are fund managers seeing in CSL?

CSL takes the top spot

Morgan Stanley’s research found healthcare extended its lead as the most favoured sector among Australian active fund managers during August.

CSL saw a significant increase in fund holdings, pushing it into the top spot among active positions.

An active overweight means a fund holds a larger weighting in a stock than it has in its benchmark index.

But it was a different story for some of the other bigger companies.

Managers remained underweight financials, particularly the major banks, although insurance stocks continued to attract interest.

In resources, managers increased their underweight position in BHP Group Ltd (ASX: BHP).

They also reduced their overweight exposure to Rio Tinto Ltd (ASX: RIO), while adding to gold holdings.

What’s behind the buying?

CSL’s latest results might help explain some of that interest, although there’s still plenty of work to do.

Its FY26 results showed revenue of US$15.8 billion, down 1% in constant currency.

Underlying NPATA fell 2% to US$3.1 billion, while restructuring costs and impairments contributed to a US$2.6 billion statutory loss.

But the business still managed to generate US$3.5 billion in operating cash flow.

CSL also completed an $1 billion share buyback during FY26 and announced another program worth up to $1.15 billion.

There’s also continued demand for immunoglobulin treatments, while sales of newer therapies Andembry and Hemgenix are growing.

Andembry generated US$240 million in sales during its first full year, while Hemgenix sales increased 25%.

What happens next for CSL shares?

CSL expects revenue to remain broadly unchanged in FY27, with underlying net profit forecast to grow approximately 5% in constant currency.

Its Behring division is targeting mid to single digit revenue growth, while Seqirus expects low to single digit growth.

However, Vifor remains a challenge, with revenue expected to decline approximately 25% amid generic competition and other product-related issues.

Brokers are also divided on where CSL shares could go from here.

Morgan Stanley has a $182 price target, while RBC Capital Markets is more optimistic at $213. Citi is more cautious at $160.

CSL’s AGM on 27 October will give investors another chance to hear how its recovery plans are progressing.

The post Fund managers are loading up on CSL shares. Here’s why appeared first on The Motley Fool Australia.

More reading

• Forget BHP and buy this ASX copper stock
• How much superannuation do I need to earn $2,000 per week in passive income?
• 6 ASX 200 shares scoring renewed buy calls this week
• Buy, hold, sell: BHP, CSL, and Westpac shares
• BHP shares fall as mining operations grind to a halt

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended BHP Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.